Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DLGAP2 antisense RNA 1 (DLGAP2-AS1)
- Target
- DLGAP2-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other
01
Overview
DLGAP2 antisense RNA 1 (DLGAP2-AS1) is a long non-coding RNA (lncRNA) transcribed antisense to the DLGAP2 gene. It is implicated in the regulation of gene expression primarily through acting as a molecular sponge for microRNAs that suppress oncogenic signaling pathways. DLGAP2-AS1 is overexpressed in a range of cancers and promotes tumor progression, invasion, and epithelial–mesenchymal transition (EMT), notably in hepatocellular carcinoma, by regulating the IL-6/JAK2/STAT3 and Wnt/β-catenin pathways[2][3]. It is being studied as a potential therapeutic target and prognostic biomarker in oncology, although no approved drugs currently target DLGAP2-AS1 directly[2][3][4].
- Other names
- DLGAP2-AS1Discs large-associated protein 2 antisense RNA 1
02
Mechanism of action
Acts as a competing endogenous RNA (ceRNA) by sponging microRNAs (such as miR-26a-5p and miR-26b-5p), Deregulates expression of oncogenic factors (e.g., IL-6), Activates JAK2/STAT3 pathway, Activates Wnt/β-catenin signaling
03
Biological functions
Regulation of gene expressionPromotion of epithelial–mesenchymal transition (EMT)Cell proliferationInhibition of apoptosisSignal transductionOther
04
Disease associations
Cancer (various types including hepatocellular carcinoma, gastric cancer, breast cancer, glioblastoma, colorectal cancer)Tumor progressionPrognostic markerOther
05
Safety considerations
Potential for widespread effects if targeted due to multiple roles in cancer progression and possible impacts in normal tissues
06
Biomarkers
Potential prognostic biomarker for poor outcomes in several cancersmarker for tumor progression
Beyond the preview
Go deeper on DLGAP2 antisense RNA 1 (DLGAP2-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DLGAP2 antisense RNA 1 (DLGAP2-AS1).